Theriva Biologics, Inc. (TOVX) AMEX
0.29
+0.0092(+3.26%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.29
+0.0092(+3.26%)
Currency In USD
| Previous Close | 0.28 |
| Open | 0.28 |
| Day High | 0.29 |
| Day Low | 0.27 |
| 52-Week High | 0.86 |
| 52-Week Low | 0.16 |
| Volume | 1.03M |
| Average Volume | 21.05M |
| Market Cap | 10.21M |
| PE | -0.49 |
| EPS | -0.58 |
| Moving Average 50 Days | 0.29 |
| Moving Average 200 Days | 0.29 |
| Change | 0 |
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
GlobeNewswire Inc.
Feb 18, 2026 1:00 PM GMT
- Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales milestones along with tiered single-digit royalties on net product sales - - Rasayana to assume all responsibility and costs
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
GlobeNewswire Inc.
Feb 03, 2026 1:00 PM GMT
- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress in Hong Kong on Saturd
Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
GlobeNewswire Inc.
Dec 29, 2025 1:00 PM GMT
- EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC, including sample size, repeated dosing of VCN-01, and an adaptive desi